Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Prof. Yuyan Tang | Immunology and Microbiology | Best Researcher Award

Minhang Hospital, Fudan University | China

Prof. Yuyan Tang is a clinician-scientist specializing in nephrology and molecular immunopathology, with a strong research focus on the gut–kidney axis, IgA nephropathy, and chronic kidney disease (CKD). Her studies elucidate the mechanisms by which intestinal microbiota, short-chain fatty acids (SCFAs), and NLRP3 inflammasome signaling influence renal inflammation and fibrosis, integrating molecular biology with traditional Chinese medicine interventions. She has led several competitive research projects funded by the National Natural Science Foundation of China and regional scientific bodies, advancing translational insights into renal disease mechanisms and microbiome-based therapeutic strategies. Prof. Yuyan Tang has published 23 peer-reviewed documents indexed in Scopus, garnering 287 citations across 262 citing documents, with an h-index of 8. Her scientific contributions include 8 first- or corresponding-author SCI papers with a total impact factor of 52.7, notably featuring a highly cited article in Circulation Research and impactful publications in Nephrology Dialysis Transplantation and BMC Microbiology. Recognized as a Youth Talent Awardee at Fudan University’s Affiliated Minhang Hospital, Prof. Yuyan Tang’s research continues to bridge microbiome regulation and nephrology through innovative molecular and clinical investigations.

Profile: Scopus

Featured Publications

  • Tang, Y., Zhu, Y., He, H., Sun, W., Wu, J., Xiao, Y., … Xu, X. (2024). IgA nephropathy: Gut microbiome regulates the production of hypoglycosylated IgA1 via the TLR4 signaling pathway. Nephrology Dialysis Transplantation, 39(10), 1624–1641.

  • Jiang, L., He, H., Tang, Y., Li, J., Reilly, S., Xin, H., … Cai, H. (2024). Activation of BK channels prevents diabetes-induced osteopenia by regulating mitochondrial Ca2+ and SLC25A5/ANT2-PINK1-PRKN-mediated mitophagy. Autophagy, 20(11), 2388–2404.

  • Li, H., Xu, M., Xu, X., Tang, Y., Jiang, H., Li, L., … Yang, T. (2022). Faecalibacterium prausnitzii attenuates CKD via Butyrate-Renal GPR43 Axis. Circulation Research, 131(9), e120–e134.

  • Tang, Y., Xiao, Y., He, H., Zhu, Y., Sun, W., Hu, P., … Xu, X. (2023). Aberrant gut microbiome contributes to barrier dysfunction, inflammation and local immune responses in IgA nephropathy. Kidney and Blood Pressure Research, 48(1), 261–276.

  • Tang, Y., Zhu, Y., He, H., Peng, Y., Hu, P., Wu, J., … Xu, X. (2022). Gut dysbiosis and intestinal barrier dysfunction promote IgA nephropathy by increasing the production of Gd-IgA1. Frontiers in Medicine, 9, 944027.

Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Published on by Forensic Scientist

Mrs. Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University | Poland

Mrs. Monika Prylińska-Jaśkowiak is an emerging clinician-scientist whose professional journey reflects a rare balance between medical practice, academic excellence, and translational research. She earned her Doctor of Medical Sciences degree from Collegium Medicum, Nicolaus Copernicus University in Toruń, where her doctoral research focused on the relationship between the gut microbiome and chronic fatigue syndrome, integrating clinical insight with advanced molecular and bioinformatic analyses. As a specialist pediatrician at the Voivodeship Children’s Hospital in Bydgoszcz, she combines her research background with everyday patient care and is currently pursuing specialization in pediatric rheumatology. Her scientific contributions include peer-reviewed publications such as The gut microbial composition is different in chronic fatigue syndrome than in healthy controls (Scientific Reports, 2025), and review papers in the Journal of Education, Health and Sport (2022), widely cited for summarizing current knowledge on CFS/ME and human gut microbiota. Mrs. Monika Prylińska-Jaśkowiak’s research interests encompass pediatric immunology, microbiome–immune interactions, and chronic inflammatory diseases, with a focus on precision diagnostics and targeted therapy development. Actively engaged in professional societies including the Polish Pediatric Society and the Polish Society of Vaccinology, she continues to expand her expertise through certified courses in resuscitation, vaccinology, and emergency pediatrics. Her commitment to continuous learning, clinical excellence, and evidence-based innovation exemplifies the spirit of a modern physician-scientist dedicated to improving child health and advancing medical science.

Profile: ORCID | LinkedIn

Featured Publications

• Prylińska, M., & Kożuchowski, M. (2022, September 28). The human gastrointestinal tract microbiota in health – current knowledge summary. Journal of Education, Health and Sport, 12(10). https://doi.org/10.12775/JEHS.2022.12.10.005

• Kożuchowski, M., & Prylińska, M. (2022, April 30). The proper functioning of the sense of smell and its disturbances on the example of COVID-19 infection. Journal of Education, Health and Sport, 12(4). https://doi.org/10.12775/JEHS.2022.12.04.026

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.

Guoying Ni | Microbiology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Guoying Ni | Microbiology | Best Researcher Award

CEO | Zhongao Biomedical Technology (Guangdong) Co., Ltd | Australia

Dr. Guoying Ni is an esteemed researcher specializing in the tumor microenvironment and immunotherapy. With a PhD from Griffith University School of Medicine, Australia, Dr. Ni has dedicated nearly 15 years to groundbreaking research at the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Dr. Ni’s research has led to significant advancements, including the application of nanostructured graphene oxide for targeted immunotherapy and the discovery of tumor-inhibiting properties of Caerin peptides from Australian tree frogs.

Profile

Scopus

Strengths for the Awards

  • Extensive Research Experience – Dr. Ni has been engaged in tumor microenvironment and immunotherapy research for nearly 15 years across multiple institutions in Australia and China.
  • Innovative Contributions – Key contributions include using nanostructured graphene oxide for IL-10R antibody delivery and discovering the tumor-inhibitory effects of Caerin peptides.
  • High-Impact Publications – With nearly 60 research papers published in prestigious journals (Q1-ranked, impact factor over 12), Dr. Ni’s work demonstrates strong academic influence.
  • Funding and Grants – Dr. Ni has secured over 20 million RMB in research funding, showing recognition and support from funding bodies.

Education 🎓

Dr. Ni obtained a PhD from Griffith University School of Medicine, Australia. During this time, extensive research in immunotherapy and molecular biology laid the foundation for Dr. Ni’s expertise in cancer treatment methodologies.

Experience 🌟

Dr. Ni has held pivotal research positions at multiple prestigious institutions, including the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Key contributions include developing a novel antibody delivery system using graphene oxide nanoparticles and evaluating anti-IL-10R antibody peptides in vitro and in vivo. Additionally, Dr. Ni has over eight years of experience supervising master’s and PhD students across Australia and China.

Research Interest On Microbiology 📚

Dr. Ni’s research focuses on tumor immunotherapy, nanomedicine, and molecular oncology. Notable areas of interest include:

  • Graphene oxide as a targeted antibody delivery system
  • Anti-IL-10R therapy in cancer treatment
  • Caerin peptides for tumor suppression and immune response activation
  • Peptide-based immunotherapies for clinical applications

Awards & Honors 🏆

  • 2022-2023: DVCR/A Launch Research Grant/Award, University of the Sunshine Coast, Australia
  • 2016-2017: HDR Merit Research Grant, Griffith University, Australia
  • 2013: GRPRS Scholarship and HDR Scholarship, Griffith University
  • Visiting Professor: Guangdong Pharmaceutical University, First People’s Hospital of Foshan, Guangdong Province

Publications 📄

  1. Title: Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Ni, G.; Wang, T.
    • Publication Year: 2024
    • Citations: 0
  2. Title: Caerin 1.9–Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles
    • Authors: Long, Y.; Duan, X.; Fu, Q.; … Liu, X.; Yang, W.
    • Publication Year: 2024
    • Citations: 0
  3. Title: Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1
    • Authors: Wang, Y.; Zhong, F.; Xiao, F.; … Wang, T.; Zhang, W.
    • Publication Year: 2024
    • Citations: 1
  4. Title: Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
    • Authors: Fu, Q.; Luo, Y.; Li, J.; … Wang, T.; Ni, G.
    • Publication Year: 2024
    • Citations: 0
  5. Title: Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii
    • Authors: Zhang, P.; Tang, S.; Fu, Q.; … Chen, G.; Liu, X.
    • Publication Year: 2023
    • Citations: 2
  6. Title: Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
    • Authors: Liu, X.; Ni, G.; Zhang, P.; … Yuan, S.; Wang, T.
    • Publication Year: 2023
    • Citations: 10
  7. Title: Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
    • Authors: Cavallazzi Sebold, B.; Li, J.; Ni, G.; … Liu, X.; Wang, T.
    • Publication Year: 2023
    • Citations: 6
  8. Title: Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts
    • Authors: He, T.; Du, J.; Zhu, K.; … Zhang, P.; Yuan, J.
    • Publication Year: 2023
    • Citations: 2
  9. Title: Degradation of differently processed Mg-based implants leads to distinct foreign body reactions (FBRs) through dissimilar signaling pathways
    • Authors: Liu, X.; Chen, G.; Zhong, X.; … Gao, M.; Li, H.
    • Publication Year: 2023
    • Citations: 5
  10. Title: PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
  • Authors: Cavallazzi Sebold, B.; Ni, G.; Li, J.; … Liu, X.; Wang, T.
  • Publication Year: 2023
  • Citations: 3

Conclusion 🎉

Dr. Guoying Ni is a trailblazer in tumor immunotherapy and nanomedicine. With numerous research contributions, multiple prestigious awards, and collaborations with globally recognized scientists, Dr. Ni continues to push the boundaries of medical research to develop innovative cancer treatments. Through dedication and expertise, Dr. Ni’s work is making a significant impact on the future of cancer immunotherapy.

Fizza Khalid | microbiology | Best Researchrer Award

Published on by Forensic Scientist

Dr. Fizza Khalid | microbiology | Best Researcher Award

clinical scientist at Dr Sulaiman Al-Habib Medical Diagnostic Laboratory , Saudi Arabia

Dr. Fizza Khalid is a dedicated microbiologist with extensive expertise in laboratory research, antimicrobial resistance, and clinical microbiology. With a Ph.D. in Medical Microbiology from the University of Health Sciences, Lahore, she has a proven track record of characterizing drug-resistant bacteria and developing innovative treatment strategies. Currently, she is the Deputy Head of the Clinical Research Committee and a Specialized Lab Supervisor at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. Dr. Khalid is passionate about advancing microbiological research to improve healthcare outcomes and has published several impactful studies in leading international journals.

Profile

ORCID

Educational

  • Ph.D. in Medical Microbiology (2016–2023) – University of Health Sciences, Lahore
    Thesis: Characterization of Locally Isolated Acinetobacter baumannii Strains for Drug Resistance and Biofilm Formation
  • M.Phil. in Medical Microbiology (2012–2014) – University of Health Sciences, Lahore
    Thesis: In-vitro Efficacy of Polymyxin B with Rifampin, Colistin, and Doxycycline Against Extensively Drug Resistant Acinetobacter baumannii
  • M.Sc. in Medical Technology (2008–2010) – University of Health Sciences, Lahore
    Thesis: Frequency of Extended Spectrum Beta Lactamase Enzymes in the Clinical Isolates of Salmonella Typhi
  • B.Sc. in Medical Laboratory Technology (2005–2007) – University of Health Sciences, Lahore

Professional Experience

Dr. Fizza Khalid currently serves as the Deputy Head of the Clinical Research Committee and Specialized Lab Supervisor in Microbiology at MD Lab, Dr. Sulaiman AlHabib Medical Group, Saudi Arabia. In her role, she leads clinical microbiology operations, collaborates with healthcare professionals, ensures regulatory compliance, and conducts research presented at international conferences. Previously, she was a Senior Lab Technologist at the same group, where she developed standard operating protocols, performed clinical microbiology analysis, and ensured testing quality and safety compliance. Throughout her career, Dr. Khalid has mentored junior researchers, promoted clinical research, and conducted workshops to enhance scientific study design and writing skills.

Research Interests

Dr. Khalid’s research focuses on antimicrobial resistance, particularly in Acinetobacter baum                                                                                             annii and Salmonella Typhi, biofilm formation, and the effectiveness of novel treatment strategies against drug-resistant bacterial strains. She has a keen interest in developing antimicrobial agents, studying bacterial genotyping, and investigating synergistic antibiotic combinations to combat multidrug-resistant pathogens. Her research contributes to understanding the molecular mechanisms of resistance and finding practical applications for improving patient care in clinical settings.

Author Metrics

  • Published Papers: 14 peer-reviewed articles, including journals such as Clinica Chimica Acta, JPMA, Scientific Reports, and Annals of Clinical Microbiology and Antimicrobials.
  • Citations: Her work has been widely cited in the fields of antimicrobial resistance and biofilm research.
  • H-index: Reflects her contributions to microbiology, particularly in research related to Acinetobacter baumannii and Salmonella Typhi.

Publication

Conclusion

Fizza Khalid presents an excellent case for the Best Researcher Award in medical microbiology, with notable strengths in antibiotic resistance research, an impressive publication record, and practical lab expertise. Her leadership role in facilitating junior researchers and fostering a culture of research also speaks to her broader contribution to the scientific community. With a few targeted improvements, such as securing international collaborations and focusing her research scope, she can further strengthen her candidacy for the award.

In conclusion, Khalid’s achievements in medical microbiology, particularly her work on MDR pathogens, make her a strong contender for the Best Researcher Award, demonstrating both scientific excellence and leadership in her field.